BitGo Holdings announced on Jan. 12 that it is targeting a valuation of up to $1.96 billion in what could be the first ...
In 2025, Fundsmith Equity Fund began building a position in Zoetis, while the company reported third-quarter revenue growth and addressed safety concerns surrounding its Librela osteoarthritis ...
Derbyshire Times on MSN
New wellbeing garden in Chesterfield and garden rooms in Grassmoor and Clowne are given the green light by planning authorities
Scarsdale Health Centre, Nightingale Close, Chesterfield: Redevelopment to provide a wellbeing garden, including landscaping ...
The Texas Tribune on MSN
A blossoming Texas medical marijuana industry adds new businesses, products and patients
The Texas Department of Public Safety has issued provisional licenses to nine new medical marijuana operators while existing ones have started opening new manufacturing and cultivating facilities.
Fixed deposits are seen as safe, but are they really? Understand FD risks, inflation impact, and why real returns on FDs can ...
The Texas Hub 2025 Detailed Design base case was based on operating three Hydrogen Processing of Magnet Scrap ("HPMS") vessels, with a post-tax Net Present Value ("NPV") applying a 7% discount rate of ...
Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...
President Lee Jae-myung’s recent visit to Beijing, the first by a South Korean leader since 2019, marks a tentative reset in ...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany-- 12 January, 2026 -- Boehringer Ingelheim today announced a strategic ...
Primary aldosteronism management depends on a multitude of factors, and surgical adrenalectomy is generally recommended in ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results